<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050881</url>
  </required_header>
  <id_info>
    <org_study_id>001/DNS</org_study_id>
    <nct_id>NCT01050881</nct_id>
  </id_info>
  <brief_title>Notification of Donors With Positive Microbiology Markers</brief_title>
  <official_title>Assessment of the Impact of Notification of Blood Donors Testing Positive for Microbiology Markers: What is the Psychological Impact of Notification and Does the Method of Notification Influence the Outcome?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Blood and Transplant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Welsh Blood Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scottish National Blood Transfusion Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irish Blood Transfusion Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Blood and Transplant</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year around 200 blood donors in the UK are found to be infected with blood-borne&#xD;
      diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified&#xD;
      as having an increased risk of variant Creutzfeldt-Jakob Disease (vCJD). Although the&#xD;
      notification procedures for these infections vary, their effectiveness and appropriateness&#xD;
      have never been evaluated in a systematic study.&#xD;
&#xD;
      The proposed research has been designed to assess the responses of blood donors to&#xD;
      notification and their satisfaction with how they were informed about the infection. The&#xD;
      study will be implemented using standard questionnaire-based measures (French et al, 2004;&#xD;
      Marteau &amp; Bekker, 1992).&#xD;
&#xD;
      The study will involve approximately 600 blood donors who were informed of an infection or&#xD;
      possible infection with blood-borne diseases in 2008 and 2009, and approximately 100 donors&#xD;
      notified of possible risk of vCJD infection in 2005. A comparable group of 2005 donors will&#xD;
      be included to control for the effects of time. As the majority of donors testing positive&#xD;
      donated to NHS Blood and Transplant (NHSBT), the participants will be identified from the&#xD;
      NHSBT database only, and their availability confirmed through their GP or specialist&#xD;
      clinician. A standardized questionnaire will be then sent to all those identified as&#xD;
      eligible.&#xD;
&#xD;
      The study will last 12 months, but direct participant involvement will be limited to the time&#xD;
      required to complete the questionnaire, which should take under one hour. To safeguard&#xD;
      confidentiality, no identifiable personal data will be used in the analysis. Where&#xD;
      demographic or medical information already held by NHSBT is retrieved to minimise response&#xD;
      burden, this will be pseudonymised before use.&#xD;
&#xD;
      The study is sponsored by the blood services for England, Wales, Scotland and Northern&#xD;
      Ireland. The results will be used to inform notification procedures in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the impact of notification of blood donors testing&#xD;
      positive for microbiology markers for blood-borne and (mostly) currently incurable infections&#xD;
      (hepatitis B, hepatitis C, HIV, HTLV and vCJD). Specifically, the study will focus on donors'&#xD;
      responses to being notified of an infection or possible infection, and their satisfaction&#xD;
      with the notification process. The data collected will be used to examine predictors of&#xD;
      satisfaction and thus help inform notification procedures in the future.&#xD;
&#xD;
      In the UK, all donations are unpaid and voluntary, which is considered to be the safest&#xD;
      method of blood collection (WHO Global Database on Blood Safety (GDBS) and Blood Safety&#xD;
      Indicators). Out of the 1.9 million UK blood donations in 2008, only 187 (&gt;0.01%) tested&#xD;
      positive. With such low incidence and focus on blood safety, the deferred donor management is&#xD;
      largely informed by anecdotal evidence and historical developments. The notification process&#xD;
      is standardised within each blood service (e.g. NHSBT Management of Donors with Confirmed&#xD;
      Positive Microbiological Markers, MPD/MED/009/05), but has never been evaluated in a&#xD;
      systematic study. Worldwide, only a handful of studies have approached the issue (Tynell et&#xD;
      al, 2007; Kleinman et al, 2004), but have suggested that donors can experience confusion and&#xD;
      anxiety as a result of notification. It is therefore possible that current notification&#xD;
      procedures do not adequately address the donors' needs.&#xD;
&#xD;
      A recent in-depth qualitative study of the impact of notification of possible increased risk&#xD;
      of variant Creutzfeldt-Jacob Disease (vCJD) for public health purposes (Elam et al, awaiting&#xD;
      publication) found that notification was a shocking event in most subjects' lives, although&#xD;
      it did not have a lasting emotional impact. Several factors influenced how well information&#xD;
      given at notification was retained and implemented. As it is anticipated that all blood&#xD;
      donations are to be screened for vCJD as soon as a test becomes available, the need for the&#xD;
      development of optimal notification procedures was identified. The proposed study builds on&#xD;
      those findings.&#xD;
&#xD;
      Blood donors comprise a unique population, usually characterised by high altruism, low&#xD;
      risk-taking, conservatism and concern with health (Simmons et al., 1993; Burnett, 1981). For&#xD;
      those reasons, notification of serious infection could cause them greater distress,&#xD;
      experience of stigma and self-image damage than an average person (Jackson, 2005; Orsini,&#xD;
      2002; Schulte, 2002; Murray, 1990), and therefore should be handled with utmost care.&#xD;
&#xD;
      Currently, blood donations in the UK are routinely tested for syphilis, hepatitis B virus&#xD;
      (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and human T-lymphotropic&#xD;
      virus (HTLV). Additionally, if indicated by donor history, supplementary tests for malaria,&#xD;
      T-cruzi, cytomegalovirus (CMV), and West Nile virus (WNV) are performed. For the purposes of&#xD;
      the study, only donors notified of positive test results of routine screening will be&#xD;
      surveyed. Those testing positive for syphilis will not be included because of the universally&#xD;
      curable nature of the infection.&#xD;
&#xD;
      A mail out questionnaire was chosen as the best form of data collection because of the&#xD;
      significant dispersion of the study population, the continuity of contact method, and the low&#xD;
      intrusiveness of the instrument. Those wishing to participate will be able to complete the&#xD;
      questionnaire at a time and place most convenient to them. As initial communication was by&#xD;
      letter, it is expected that a mail out survey accompanied by a cover letter will be&#xD;
      accessible to most donors. A telephone- and a web-based survey completion option will also be&#xD;
      offered to facilitate access.&#xD;
&#xD;
      The questionnaire will focus on three main areas of interest, namely satisfaction, emotional&#xD;
      response and understanding. These were identified from the in-depth vCJD study, donor records&#xD;
      and literature review as the issues most pertinent to the notification process, and ones&#xD;
      influenced by the manner in which information is provided. Personal characteristics and&#xD;
      circumstances will not be considered, as they are already well researched from the&#xD;
      perspective of coping (Kaye &amp; Raghavan, 2002; Baile et al., 2000; Kraus et al., 2000; Buckman&#xD;
      &amp; Kason, 1992), and not controlled for in blood donation, thus limiting their usefulness for&#xD;
      informing donor notification process.&#xD;
&#xD;
      To ensure the appropriateness and feasibility of questions, and to avoid misrepresentation,&#xD;
      the survey will be piloted with a small sample of donors testing positive in routine&#xD;
      screening in 2007.&#xD;
&#xD;
      The return of a completed questionnaire will be treated as implied consent, and the return of&#xD;
      an empty one with or without the opt-out option selected will be taken to signify the donor's&#xD;
      decision not to give such consent.&#xD;
&#xD;
      The main risk identified in contacting positive donors is re-traumatisation, and a helpline&#xD;
      number will be provided to allow those experiencing any distress to discuss their situation.&#xD;
      It is hoped, however, that as the infections under study are chronic, re-traumatisation would&#xD;
      be rare and minimal. It is further hoped that the character of the project, which aims to aid&#xD;
      the development of notification procedures that would be the most satisfactory to donors&#xD;
      receiving positive test results in the future, would be welcome by most subjects as an&#xD;
      opportunity to engage in an activity that could be of benefit to others. Should any donor's&#xD;
      reaction suggest that their situation may be serious, every attempt will be made to offer&#xD;
      follow-up care. Any aggravating issues inherent in the questionnaire itself, however, will&#xD;
      hopefully be identified and rectified at the piloting stage. The direct donor burden, should&#xD;
      they choose to participate in the study, should be limited to the 20-30 minutes needed to&#xD;
      complete the questionnaire.&#xD;
&#xD;
      Only the Principal Investigator and the researcher will have access to identifiable personal&#xD;
      data, the PI as a member of the donor's healthcare team, and the researcher within the remit&#xD;
      of the position. The researcher's access to and use of donor records will comply with the&#xD;
      Good Clinical Practice guidelines, and further with the NHS Confidentiality Code of Practice.&#xD;
      Donor name and number will be coded and stored separately from the pseudonymised survey data.&#xD;
      The file linking donor identifiable information with codes will be stored for the duration of&#xD;
      the research project only. The raw survey data file and returned questionnaires will be&#xD;
      stored securely for a minimum of 2 years. Only the pseudonymised data will be used for&#xD;
      analysis, and no identifiable donor information will be included in ensuing reports.&#xD;
&#xD;
      The demographic data such as age, ethnicity and sex already available in the donor records&#xD;
      will be pseudonymised and used to reduce response burden. Only the data theoretically&#xD;
      relevant to the study will be included. The access to all study files will be restricted, and&#xD;
      all information will be stored and shared securely as per NHS guidelines. No identifiable&#xD;
      personal data will be shared.&#xD;
&#xD;
      The survey data will be statistically analysed using SPSS. Every attempt will be made to&#xD;
      assess the extent of the non-response error using pseudonymised demographic data of the&#xD;
      non-respondents. Due to the large number of variables involved, main attention will be given&#xD;
      to descriptive statistics.&#xD;
&#xD;
      To avoid misinterpretation, any conclusions drawn from the data will be discussed by the&#xD;
      Project Management Group and not made by the researcher in isolation. The results of the&#xD;
      study will be published and accessible to the participants and general public in this way, or&#xD;
      if requested directly.&#xD;
&#xD;
      Both the PI and the researcher are the employees of the NHSBT. The proposed research project&#xD;
      is funded by the four UK blood services, and aims to improve the service offered. It will&#xD;
      consider all responses, and use them to the benefit of the service users; however, it is&#xD;
      intended to investigate the responses of blood donors who have donated in England or North&#xD;
      Wales only. Due to the unique characteristics of this group, without further study the&#xD;
      results cannot be generalised to the entire UK population or to other countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure for the study is the reported level of satisfaction with the notification process, including the information provided and the donor's emotional response.</measure>
    <time_frame>June-July 2010</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis C</condition>
  <condition>Human T-lymphotropic Virus I &amp; II</condition>
  <condition>Creutzfeldt-Jakob Syndrome</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Positive Blood Donors</arm_group_label>
    <description>Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors and patients notified of increased risk of vCJD in 2005.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All donors testing positive for microbiology markers in 2008 and 2009, and those identified&#xD;
        as at risk of vCJD in 2008.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  deferred blood donor status, and&#xD;
&#xD;
          -  deferral due to a positive result of a routine blood test for HIV, or hepatitis B, or&#xD;
             hepatitis C, or HTLV, or having been identified as at risk of vCJD; and&#xD;
&#xD;
          -  deferral occured in 2008 or 2009 (2007 for the pilot; 2005 for those at risk of vCJD&#xD;
             and the control group); and&#xD;
&#xD;
          -  donor registered at one of the NHSBT centres (English Blood Service in England and&#xD;
             Wales);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not a blood donor; or&#xD;
&#xD;
          -  no record of notification having taken place; or&#xD;
&#xD;
          -  a member of Armed Forces or other profession where contact at the address provided&#xD;
             could lead to a breach of confidentiality; or&#xD;
&#xD;
          -  deferred before 2008 (if not in the pilot or notified of increased risk of vCJD);&#xD;
&#xD;
          -  deferred as a result of a non-routine test or syphilis infection only; or&#xD;
&#xD;
          -  donor registered with and notified by the Welsh, Scottish or Northern Irish Blood&#xD;
             Services;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia E Hewitt, FRCP FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Blood and Transplant</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theresa M Marteau, PhD FMedSci</last_name>
    <role>Study Director</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cameron F Paige, MSc</last_name>
    <role>Study Director</role>
    <affiliation>NHS Blood and Transplant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cameron F Paige, MSc</last_name>
    <phone>+44 (0)208 271 6329</phone>
    <email>cameron.paige@nhsbt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia E Hewitt, FRCP FRCPath</last_name>
    <phone>+44 (0)20 8271 6331</phone>
    <email>patricia.hewitt@nhsbt.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHS Blood and Transplant, Transfusion Microbiology</name>
      <address>
        <city>Colindale</city>
        <state>London</state>
        <zip>NW9 5BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Cameron F Paige, MSc</last_name>
      <phone>+44 (0)208 271 6329</phone>
      <email>cameron.paige@nhsbt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Patricia E Hewitt, FRCP FRCPath</last_name>
      <phone>020 8271 6331</phone>
      <email>patricia.hewitt@nhsbt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia E Hewitt, FRCP FRCPath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.who.int/bloodsafety/en/</url>
    <description>WORLD HEALTH ORGANISATION, ca. 2009. Blood transfusion safety: Universal access to safe blood and blood products for transfusion.</description>
  </link>
  <reference>
    <citation>Elam G, Oakley K, Connor N, Hewitt P, Ward HJ, Zaman SM, Chow Y, Marteau TM. Impact of being placed at risk of Creutzfeldt-Jakob disease: a qualitative study of blood donors to variant CJD cases and patients potentially surgically exposed to CJD. Neuroepidemiology. 2011;36(4):274-81. doi: 10.1159/000328646. Epub 2011 Jul 12.</citation>
    <PMID>21757956</PMID>
  </reference>
  <reference>
    <citation>French DP, Maissi E, Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer. 2004 Nov 29;91(11):1887-92.</citation>
    <PMID>15534608</PMID>
  </reference>
  <reference>
    <citation>Kleinman S, Wang B, Wu Y, Glynn SA, Williams A, Nass C, Ownby H, Busch MP; Retrovirus Epidemiology Donor Study. The donor notification process from the donor's perspective. Transfusion. 2004 May;44(5):658-66.</citation>
    <PMID>15104645</PMID>
  </reference>
  <reference>
    <citation>Tynell E, Norda R, Ekermo B, Sanner M, Andersson S, Bj√∂rkman A. False-reactive microbiologic screening test results in Swedish blood donors-how big is the problem? A survey among blood centers and deferred donors. Transfusion. 2007 Jan;47(1):80-9.</citation>
    <PMID>17207234</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>February 12, 2010</last_update_submitted>
  <last_update_submitted_qc>February 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Patricia E Hewitt (Principal Investigator) - Consultant Specialist in Transfusion Microbiology</name_title>
    <organization>NHS Blood and Transplant</organization>
  </responsible_party>
  <keyword>blood donor notification</keyword>
  <keyword>emotional response</keyword>
  <keyword>variant Creutzfeldt-Jacob Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Creutzfeldt-Jakob Syndrome</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 19, 2017</submitted>
    <returned>July 11, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

